Lancet
Audio Summaries

Current advancements in the care of peripheral arterial disease: modern approaches to medical, endovascular, and surgical treatment

Sep 22, 2026

The authors review current advancements in the management of peripheral arterial disease (PAD), particularly focusing on the effectiveness of medical therapy, supervised exercise, and the judicious use of revascularization procedures. They aim to address how to optimize treatment strategies to reduce cardiovascular risks, improve quality of life, and minimize limb loss in patients with varying severity of PAD. The paper highlights the complexities of PAD management due to its multifaceted nature and the potential overuse of invasive interventions.

Peripheral arterial disease: adverse impacts, disparities in outcomes, and the path ahead

Sep 22, 2026

This paper aims to address the adverse impacts of peripheral arterial disease (PAD) and the disparities in outcomes among affected populations. The authors highlight the significant individual and societal burdens of PAD, particularly on underserved groups, and propose both short-term and long-term strategies to improve management and access to care, including enhanced awareness and multidisciplinary treatment approaches. The study emphasizes the need for targeted interventions to reduce the prevalence and consequences of PAD, especially in vulnerable communities.

Understanding peripheral arterial disease in the current era

Sep 22, 2026

The authors aim to address the underacknowledgment, underdiagnosis, and undertreatment of peripheral arterial disease (PAD) in the context of atherosclerotic cardiovascular disease, highlighting its increasing prevalence and significant mortality rates. They emphasize the need for improved recognition and interdisciplinary measures to enhance patient outcomes and advocate for better integration of preventive care and treatment strategies. This clinical series seeks to inform clinicians and policymakers about the global burden of PAD and effective approaches to manage it.

Developing roadmaps for advancing practice, research, and policy in the arts and health

Sep 21, 2026

The authors aim to develop actionable roadmaps for integrating the arts into health and wellbeing systems globally, addressing the emerging evidence of arts engagement's health benefits. They propose key strategies, including ensuring universal access to arts opportunities, implementing population-level approaches to tackle health inequities, and fostering clinical innovation in arts therapies. Additionally, they highlight the importance of cross-sector collaboration and investment to support these initiatives.

Precision prevention and early detection: framework for a new clinical cancer control pathway

Sep 18, 2026

The authors explore how precision prevention and early detection (PPED) can improve cancer control by identifying individuals at elevated risk and tailoring interventions accordingly. They emphasize the importance of both escalating preventive care for high-risk individuals and de-escalating interventions for low-risk individuals, while also highlighting the need for a robust health-system infrastructure to support ongoing prevention efforts. The paper addresses the challenge of enhancing cancer survival rates through better screening and preventive strategies.

Switch to injectable cabotegravir-rilpivirine given every 8 weeks in adolescents living with HIV with virological suppression in sub-Saharan Africa (LATA): a randomised, open-label, multicentre, 96-week non-inferiority trial

Sep 17, 2026

The study aimed to evaluate the efficacy and safety of long-acting injectable (LAI) cabotegravir-rilpivirine compared to daily oral antiretroviral therapy (TLD) in adolescents living with HIV who have achieved virological suppression. Results showed that LAI cabotegravir-rilpivirine was not only non-inferior but also superior to TLD in maintaining virological suppression over 96 weeks, with no new safety concerns identified. These findings suggest that LAI cabotegravir-rilpivirine could be a viable maintenance treatment option for this population in sub-Saharan Africa.

Most-favoured-nation pricing for prescription drugs in US Medicare: a cohort study

Sep 13, 2026

This study aimed to model the impact of the most-favoured-nation payment models (GLOBE and GUARD) on Medicare spending for prescription drugs in the U.S. The findings indicated that these models could reduce net Medicare spending by approximately $5.2 billion (16.1%) under GLOBE and $6.4 billion (17.6%) under GUARD, with significant potential savings exceeding annual sales in reference countries, raising concerns about manufacturer behavior in response to these pricing models.

Immunogenicity of fractional one-fifth and one-half doses of 17DD yellow fever vaccine compared with full dose in children aged 9-23 months in Uganda: a phase 4, single-blind, randomised clinical trial

Sep 11, 2026

This study aimed to evaluate the immunogenicity of fractional doses (one-fifth and one-half) of the 17DD yellow fever vaccine compared to the full dose in children aged 9-23 months in Uganda. The findings demonstrated that both fractional doses were non-inferior to the full dose in terms of seroconversion, suggesting their potential use for vaccination during supply shortages in young children.

Efficacy and safety of mitapivat in adults with transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE-T): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

Sep 10, 2026

The authors aimed to evaluate the efficacy and safety of mitapivat, an oral allosteric activator of pyruvate kinase, in adults with transfusion-dependent α-thalassaemia or β-thalassaemia. The phase 3 trial found that mitapivat significantly reduced the transfusion burden compared to placebo, with a favorable safety profile, marking it as the first oral disease-modifying therapy for these conditions.

Perioperative durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable gastric and gastro-oesophageal junction adenocarcinoma (MATTERHORN): final results of overall survival and event-free survival by pathological response in a global, randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

Sep 9, 2026

The authors of the MATTERHORN trial aimed to evaluate the impact of perioperative durvalumab combined with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) on overall survival in patients with resectable gastric and gastro-oesophageal junction adenocarcinoma. The study found that overall survival significantly improved in the durvalumab group compared to the placebo group, establishing durvalumab plus FLOT as a new standard treatment option for this patient population.